Coenzyme Q10 supplementation improves adipokine profile in dyslipidemic individuals: a randomized controlled trial

Table 1 Number of participants that with metabolic related disorders before and after intervention

Disorders n (%)	Placebo (n = 50)			CoQ10 (n = 51)			p₃^c	p₄^d
Disorders n (%)	Baseline	24-week	p₁^a	Baseline	24-week	p₂^b	p₃^c	p₄^d
Prediabetes^e	32 (64.0)	30 (60.0)	0.680	25 (49.0)	13 (25.5)	0.014	0.125	< 0.001
IR^f	49 (98.0)	47 (94.0)	0.307	49 (96.1)	40 (78.4)	0.008	0.570	0.024
Mets^g	30 (60.0)	28 (56.0)	0.685	35 (68.6)	18 (35.3)	0.001	0.365	0.037

^ap₁ values were calculated by chi-square tests for differences between baseline and 24th week in placebo groups
^bp₂ values were calculated by chi-square tests for differences between baseline and 24th week in CoQ10 groups
^cp₃ values were calculated by chi-square tests for differences between two group at baseline
^dp₄ values were calculated by chi-square tests for differences between two group at 24th week
^eDefined as 7.0 > fast blood glucose ≥ 5.6 mmol/L or 126 > fast blood glucose ≥ 100.8 mg/dL
^fIR, insulin resistance, define as HOMA-IR index > 1
^gMets, metabolic syndromes, defined according to National Cholesterol Education Program Adult Treatment Panel III (2005 American Heart Association revised edition) definition

ISSN: 1743-7075